Biomarkers of inflammation in patients with unclassified polyarthritis and early rheumatoid arthritis. Relationship to disease activity and radiographic outcome

L.S. Knudsen; M. Klarlund; H. Skjodt; Tim Jensen; Morten Østergaard; Karl Erik Jensen; Michael Sejer Hansen; Merete Lund Hetland; Hans Jørgen Nielsen; J.S. Johansen; Lene S Knudsen; Mette Klarlund; Henrik Skjødt; Trine Jensen; Mikkel Ostergaard; Karl Erik Jensen; Michael S Hansen; Merete L Hetland; Hans J Nielsen; Julia S Johansen

Biomarkers of inflammation in patients with unclassified polyarthritis and early rheumatoid arthritis. Relationship to disease activity and radiographic outcome

L.S. Knudsen, M. Klarlund, H. Skjodt, Tim Jensen, Morten Østergaard, Karl Erik Jensen, Michael Sejer Hansen, Merete Lund Hetland, Hans Jørgen Nielsen, J.S. Johansen, Lene S Knudsen, Mette Klarlund, Henrik Skjødt, Trine Jensen, Mikkel Ostergaard, Karl Erik Jensen, Michael S Hansen, Merete L Hetland, Hans J Nielsen, Julia S Johansen

45 Citations (Scopus)

Abstract

OBJECTIVE: To determine plasma interleukin 6 (pIL-6), plasma vascular endothelial growth factor (pVEGF), and serum (s) YKL-40 in patients with early rheumatoid arthritis (RA) and unclassified polyarthritis (PA), and investigate their relationship with radiographic outcome. METHODS: pIL-6 and pVEGF were determined by ELISA and sYKL-40 by an in-house radioimmunoassay in 51 patients with early RA and 21 with PA. Patients were followed with clinical and biochemical measurement every month for 2 years. Conventional radiographs of hands, wrists, and forefeet were scored according to the Larsen method, and magnetic resonance imaging of 2nd to 5th metacarpophalangeal joints of the dominant hand were evaluated for presence or absence of bone erosions. RESULTS: Baseline pIL-6, pVEGF, sYKL-40, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) were elevated in RA patients compared to healthy persons (p < 0.001), but were not in patients with PA. Patients with early RA had higher pIL-6 (p = 0.007), pVEGF (p = 0.02), and sYKL-40 (p = 0.024) compared to PA patients. pIL-6, sYKL-40, CRP, and ESR but not pVEGF decreased in patients that responded to treatment after 2 years. The mean value of pIL-6 during the first and second year were higher in patients with early RA with progression in bone erosions (n = 14) compared to early RA patients without progression (n = 30; first year 8.4 vs 2.8 ng/l, p = 0.04; second year 6.1 vs 3.6 ng/l, p = 0.03). CONCLUSION:Plasma IL-6 was the only biomarker related to treatment response and progressive erosive disease in patients with early RA, but it may not give additional information compared to CRP in relation to disease activity and treatment response.

Original language	English
Journal	Journal of Rheumatology
Volume	35
Issue number	7
Pages (from-to)	1277-87
Number of pages	10
ISSN	0315-162X
Publication status	Published - 2008

Cite this

Knudsen, L. S., Klarlund, M., Skjodt, H., Jensen, T., Østergaard, M., Jensen, K. E., Hansen, M. S., Hetland, M. L., Nielsen, H. J., Johansen, J. S., Knudsen, L. S., Klarlund, M., Skjødt, H., Jensen, T., Ostergaard, M., Jensen, K. E., Hansen, M. S., Hetland, M. L., Nielsen, H. J., & Johansen, J. S. (2008). Biomarkers of inflammation in patients with unclassified polyarthritis and early rheumatoid arthritis. Relationship to disease activity and radiographic outcome. Journal of Rheumatology, 35(7), 1277-87.

Knudsen, LS, Klarlund, M, Skjodt, H, Jensen, T, Østergaard, M, Jensen, KE, Hansen, MS, Hetland, ML, Nielsen, HJ, Johansen, JS, Knudsen, LS, Klarlund, M, Skjødt, H, Jensen, T, Ostergaard, M, Jensen, KE, Hansen, MS, Hetland, ML, Nielsen, HJ & Johansen, JS 2008, 'Biomarkers of inflammation in patients with unclassified polyarthritis and early rheumatoid arthritis. Relationship to disease activity and radiographic outcome', Journal of Rheumatology, vol. 35, no. 7, pp. 1277-87.

@article{77014ad0064f11deb05e000ea68e967b,

title = "Biomarkers of inflammation in patients with unclassified polyarthritis and early rheumatoid arthritis. Relationship to disease activity and radiographic outcome",

abstract = "OBJECTIVE: To determine plasma interleukin 6 (pIL-6), plasma vascular endothelial growth factor (pVEGF), and serum (s) YKL-40 in patients with early rheumatoid arthritis (RA) and unclassified polyarthritis (PA), and investigate their relationship with radiographic outcome. METHODS: pIL-6 and pVEGF were determined by ELISA and sYKL-40 by an in-house radioimmunoassay in 51 patients with early RA and 21 with PA. Patients were followed with clinical and biochemical measurement every month for 2 years. Conventional radiographs of hands, wrists, and forefeet were scored according to the Larsen method, and magnetic resonance imaging of 2nd to 5th metacarpophalangeal joints of the dominant hand were evaluated for presence or absence of bone erosions. RESULTS: Baseline pIL-6, pVEGF, sYKL-40, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) were elevated in RA patients compared to healthy persons (p < 0.001), but were not in patients with PA. Patients with early RA had higher pIL-6 (p = 0.007), pVEGF (p = 0.02), and sYKL-40 (p = 0.024) compared to PA patients. pIL-6, sYKL-40, CRP, and ESR but not pVEGF decreased in patients that responded to treatment after 2 years. The mean value of pIL-6 during the first and second year were higher in patients with early RA with progression in bone erosions (n = 14) compared to early RA patients without progression (n = 30; first year 8.4 vs 2.8 ng/l, p = 0.04; second year 6.1 vs 3.6 ng/l, p = 0.03). CONCLUSION:Plasma IL-6 was the only biomarker related to treatment response and progressive erosive disease in patients with early RA, but it may not give additional information compared to CRP in relation to disease activity and treatment response.",

author = "L.S. Knudsen and M. Klarlund and H. Skjodt and Tim Jensen and Morten {\O}stergaard and Jensen, {Karl Erik} and Hansen, {Michael Sejer} and Hetland, {Merete Lund} and Nielsen, {Hans J{\o}rgen} and J.S. Johansen and Knudsen, {Lene S} and Mette Klarlund and Henrik Skj{\o}dt and Trine Jensen and Mikkel Ostergaard and Jensen, {Karl Erik} and Hansen, {Michael S} and Hetland, {Merete L} and Nielsen, {Hans J} and Johansen, {Julia S}",

note = "Times Cited: 0ArticleEnglishKnudsen, L. SHerlev Hosp, Dept Rheumatol Q107, Herlev Ringvej 75, DK-2730 Herlev, DenmarkCited References Count: 41324YDJ RHEUMATOL PUBL CO920 YONGE ST, SUITE 115, TORONTO, ONTARIO M4W 3C7, CANADATORONTO",

year = "2008",

language = "English",

volume = "35",

pages = "1277--87",

journal = "Journal of Rheumatology",

issn = "0315-162X",

publisher = "Journal of Rheumatology Publishing Co. Ltd.",

number = "7",

}

TY - JOUR

T1 - Biomarkers of inflammation in patients with unclassified polyarthritis and early rheumatoid arthritis. Relationship to disease activity and radiographic outcome

AU - Knudsen, L.S.

AU - Klarlund, M.

AU - Skjodt, H.

AU - Jensen, Tim

AU - Østergaard, Morten

AU - Jensen, Karl Erik

AU - Hansen, Michael Sejer

AU - Hetland, Merete Lund

AU - Nielsen, Hans Jørgen

AU - Johansen, J.S.

AU - Knudsen, Lene S

AU - Klarlund, Mette

AU - Skjødt, Henrik

AU - Jensen, Trine

AU - Ostergaard, Mikkel

AU - Jensen, Karl Erik

AU - Hansen, Michael S

AU - Hetland, Merete L

AU - Nielsen, Hans J

AU - Johansen, Julia S

N1 - Times Cited: 0ArticleEnglishKnudsen, L. SHerlev Hosp, Dept Rheumatol Q107, Herlev Ringvej 75, DK-2730 Herlev, DenmarkCited References Count: 41324YDJ RHEUMATOL PUBL CO920 YONGE ST, SUITE 115, TORONTO, ONTARIO M4W 3C7, CANADATORONTO

PY - 2008

Y1 - 2008

N2 - OBJECTIVE: To determine plasma interleukin 6 (pIL-6), plasma vascular endothelial growth factor (pVEGF), and serum (s) YKL-40 in patients with early rheumatoid arthritis (RA) and unclassified polyarthritis (PA), and investigate their relationship with radiographic outcome. METHODS: pIL-6 and pVEGF were determined by ELISA and sYKL-40 by an in-house radioimmunoassay in 51 patients with early RA and 21 with PA. Patients were followed with clinical and biochemical measurement every month for 2 years. Conventional radiographs of hands, wrists, and forefeet were scored according to the Larsen method, and magnetic resonance imaging of 2nd to 5th metacarpophalangeal joints of the dominant hand were evaluated for presence or absence of bone erosions. RESULTS: Baseline pIL-6, pVEGF, sYKL-40, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) were elevated in RA patients compared to healthy persons (p < 0.001), but were not in patients with PA. Patients with early RA had higher pIL-6 (p = 0.007), pVEGF (p = 0.02), and sYKL-40 (p = 0.024) compared to PA patients. pIL-6, sYKL-40, CRP, and ESR but not pVEGF decreased in patients that responded to treatment after 2 years. The mean value of pIL-6 during the first and second year were higher in patients with early RA with progression in bone erosions (n = 14) compared to early RA patients without progression (n = 30; first year 8.4 vs 2.8 ng/l, p = 0.04; second year 6.1 vs 3.6 ng/l, p = 0.03). CONCLUSION:Plasma IL-6 was the only biomarker related to treatment response and progressive erosive disease in patients with early RA, but it may not give additional information compared to CRP in relation to disease activity and treatment response.

AB - OBJECTIVE: To determine plasma interleukin 6 (pIL-6), plasma vascular endothelial growth factor (pVEGF), and serum (s) YKL-40 in patients with early rheumatoid arthritis (RA) and unclassified polyarthritis (PA), and investigate their relationship with radiographic outcome. METHODS: pIL-6 and pVEGF were determined by ELISA and sYKL-40 by an in-house radioimmunoassay in 51 patients with early RA and 21 with PA. Patients were followed with clinical and biochemical measurement every month for 2 years. Conventional radiographs of hands, wrists, and forefeet were scored according to the Larsen method, and magnetic resonance imaging of 2nd to 5th metacarpophalangeal joints of the dominant hand were evaluated for presence or absence of bone erosions. RESULTS: Baseline pIL-6, pVEGF, sYKL-40, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) were elevated in RA patients compared to healthy persons (p < 0.001), but were not in patients with PA. Patients with early RA had higher pIL-6 (p = 0.007), pVEGF (p = 0.02), and sYKL-40 (p = 0.024) compared to PA patients. pIL-6, sYKL-40, CRP, and ESR but not pVEGF decreased in patients that responded to treatment after 2 years. The mean value of pIL-6 during the first and second year were higher in patients with early RA with progression in bone erosions (n = 14) compared to early RA patients without progression (n = 30; first year 8.4 vs 2.8 ng/l, p = 0.04; second year 6.1 vs 3.6 ng/l, p = 0.03). CONCLUSION:Plasma IL-6 was the only biomarker related to treatment response and progressive erosive disease in patients with early RA, but it may not give additional information compared to CRP in relation to disease activity and treatment response.

M3 - Journal article

SN - 0315-162X

VL - 35

SP - 1277

EP - 1287

JO - Journal of Rheumatology

JF - Journal of Rheumatology

IS - 7

ER -

Biomarkers of inflammation in patients with unclassified polyarthritis and early rheumatoid arthritis. Relationship to disease activity and radiographic outcome

Abstract

Fingerprint

Cite this